Form 8-K - Current report:
SEC Accession No. 0001558370-25-003013
Filing Date
2025-03-14
Accepted
2025-03-14 17:00:12
Documents
15
Period of Report
2025-03-11
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K otlk-20250311x8k.htm   iXBRL 8-K 64322
2 EX-3.1 otlk-20250311xex3d1.htm EX-3.1 9065
  Complete submission text file 0001558370-25-003013.txt   210551

Data Files

Seq Description Document Type Size
3 EX-101.SCH otlk-20250311.xsd EX-101.SCH 4127
4 EX-101.DEF otlk-20250311_def.xml EX-101.DEF 2856
5 EX-101.LAB otlk-20250311_lab.xml EX-101.LAB 17907
6 EX-101.PRE otlk-20250311_pre.xml EX-101.PRE 11822
17 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20250311x8k_htm.xml XML 5022
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25741057
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)